- Ongoing clinical trial is the first ever to combine targeted radiotherapy conditioning, Iomab-ACT, with CAR-T cell therapy to achieve lymphodepletion along with reduction of cytokine release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback